In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota ...

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...

In a conversation with Pharmaceutical Executive DeYoung explains that an end-to-end patient support model is designed to ...

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur. The rare disease space has always been uniquely difficult for drug ...

Nishith Rastogi is the CEO and co-founder of Locus, where he leads global strategy, innovation, and product development. He drives the company’s international expansion and oversees its technology ...

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation ...

FDA authorization of semaglutide 7.2 mg once weekly was supported by two 72-week Phase III programs and reviewed under the ...

This episode of The Ron Lanton Report examines how the relationship between policy and market behavior has fundamentally shifted. Regulatory signals are now moving valuations and shaping strategic ...

Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...

Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions.

Launched in January, TrumpRx.gov is part of a series of most-favored-nation deals struck between the Trump administration and ...